The clinical study to explore the effecs of anagliptin on responses of plasma glucose and lipid in new-onset type 2 diabetic patients
Not Applicable
Recruiting
- Conditions
- ew-onset Type 2 Diabetes
- Registration Number
- JPRN-UMIN000014170
- Lead Sponsor
- Diabetes And Lifestyle Center, Tomonaga Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who take other oral hypoglycemic agent 2.Patients who are past history of hypersensitivity to anagliptin 3.Patients who are severe ketosis or diabetic coma, precoma, type 1 diabetes 4.Patients who are severe infection or perioperative, severe injury 5.Pregnant or woman of child-bearing potential 6.Patients who are severe renal dysfunction or dialysis ESRD 7.Patients who are severe hepatic dysfunction 8.Patients who are judged as inappropriate for inclusion by phsicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ApoB48(MTT), LDL-c(MTT), plasma glucose(MTT), HbA1c
- Secondary Outcome Measures
Name Time Method TC(MTT), TG(MTT), HDL-c(MTT), non-HDL-c(MTT), Body weight, Blood presure, biochemical test, general blood test etc.